Shifting Tides: Unleashing The Potential Of iPSC-Based Allogeneic Cell Therapy

As the limitations of autologous cell therapy approaches become evident, many cell therapy innovators are making the switch to allogeneic strategies. But, what is the best starting material for allogeneic cell therapy? And how can you navigate all the challenges associated to this approach? In a new article, Stem Cell Reports analyzed the history and status of clinical studies using human pluripotent stem cells (PSCs).

The Human Pluripotent Stem Cell Registry has observed a significant shift in the use of human PSCs as starting materials for cell therapies. The majority of studies up to 2017 utilized human embryonic stem cells. However, since 2018, the number of clinical studies using iPSC-based cell therapy has increased tremendously. This shift in stem cell usage and the challenges it poses are key aspects of ongoing research in the field of cell therapies. Learn how iPSCs hold potential to reduce cell variability and the costs associated with cell line development.